ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population
Authors:
- Benetti ElisaBEBenetti Elisa
- Tita RossellaTRTita Rossella
- Spiga OttaviaSOSpiga Ottavia
- Ciolfi AndreaCACiolfi Andrea
- Birolo GiovanniBGBirolo Giovanni
- Bruselles AlessandroBABruselles Alessandro
- Doddato GabriellaDGDoddato Gabriella
- Giliberti AnnaritaGAGiliberti Annarita
- Marconi CaterinaMCMarconi Caterina
- Musacchia FrancescoMFMusacchia Francesco
- Pippucci TommasoPTPippucci Tommaso
- Torella AnnalauraTATorella Annalaura
Preprint
Abstract
In December 2019, an initial cluster of interstitial bilateral pneumonia emerged in Wuhan, China. A human-to-human transmission was assumed and a previously unrecognized entity, termed coronavirus-disease-19 (COVID-19) due to a novel coronavirus (SARS-CoV-2) was described. The infection has rapidly spread out all over the world and Italy has been the first European country experiencing the endemic wave with unexpected clinical severity in comparison with Asian countries. It has been shown that SARS-CoV-2 utilizes angiotensin converting enzyme 2 (ACE2) as host receptor and host proteases for cell surface binding and internalization. Thus, a predisposing genetic background can give reason for inter-individual disease susceptibility and/or severity. Taking advantage of the Network of Italian Genomes (NIG), here we mined whole-exome-sequencing data of 6930 Italian control individuals from five different centers looking for ACE2 variants. A number of variants with a potential impact on protein stability were identified. Among these, three more common missense changes, p.(Asn720Asp), p.(Lys26Arg), p.(Gly211Arg) were predicted to interfere with protein structure and stabilization. Rare variants likely interfering with the internalization process, namely p.(Leu351Val) and p.(Pro389His), predicted to interfere with SARS-CoV-2 spike protein binding, were also observed. Comparison of ACE2 WES data between a cohort of 131 patients and 258 controls allowed identifying a statistically significant (P value <0,029) higher allelic variability in controls compared to patients. These findings suggest that a predisposing genetic background may contribute to the observed inter-individual clinical variability associated with COVID-19, allowing an evidence-based risk assessment leading to personalized preventive measures and therapeutic options.Keywords
All Related Versions
- Published version: European Journal of Human Genetics, 28 (11), 1602.
This publication has 33 references indexed in Scilit:
- Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and mythsJournal of Microbiology, Immunology and Infection, 2020
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2Cell Discovery, 2020
- Structural basis for the recognition of the 2019-nCoV by human ACE2bioRxiv, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- A novel coronavirus outbreak of global health concernThe Lancet, 2020
- A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family clusterThe Lancet, 2020
- A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus EntryJournal of Virology, 2011
- Receptor and viral determinants of SARS‐coronavirus adaptation to human ACE2The EMBO Journal, 2005